UNCY - Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting | Benzinga
LOS ALTOS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company or "Unicycive"), today announced that two posters related to the Company's lead product candidate, oxylanthanum carbonate (OLC), will be presented at the National Kidney Foundation Spring Clinical Meeting taking place May 14-18, 2024, in Long Beach, California.
"We are proud to present two posters related to OLC at the National Kidney Foundation Spring Clinical Meeting, one of the premier medical conferences for the healthcare community focused on kidney disease," said Shalabh Gupta, MD, Chief Executive Officer of Unicycive. "Importantly, we will present new data from the bioequivalence study for OLC. We will also present results of a survey conducted to understand why patients may be non-compliant in taking the currently prescribed phosphate binders. We look forward to contributing meaningful results to this important event."
| Title: |
| Two-Way Crossover Study to Establish Pharmacodynamic Bioequivalence Between Oxylanthanum Carbonate and Lanthanum Carbonate |
| Lead Author: |
| Vandana Mathur, MD |
| Dates/Times: |
| Tuesday, May 14, 2024 from 3:00 p.m. – 5:00 p.m. PT |
| Wednesday, May 15, 2024 from 8:00 a.m. – 3.00 p.m. PT |
| Title: |
| Renal Dietitians Perceive Phosphate Binder and Low-Phosphate Diet Non-Compliance as Top Reasons for Above Target Serum Phosphorous Concentrations |
| Lead Author: |
| Kathleen Hill Gallant, PH.D. |
| Date/Time: |
| Tuesday, May 14, 2024 from 3:00 p.m. – 5:00 p.m. PT |
| Wednesday, May 15, 2024 from 8:00 a.m. – 3.00 p.m. PT |
About Oxylanthanum Carbonate (OLC)
Oxylanthanum carbonate is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being ...